Metastatic Endocrine Refractory
1 clinical trials · Condition
◉ Watch Metastatic Endocrine Refractory
| Record | Firm | Date |
|---|---|---|
| A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma (NCT07229417) | M.D. Anderson Cancer Center | 2025-10-22 |
Track Metastatic Endocrine Refractory automatically
Every clearance here is in the API, with alerts when new ones post.